A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 05 2020
18 05 2020
Historique:
received:
26
09
2019
accepted:
29
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
2
12
2020
Statut:
epublish
Résumé
While alpha-blockers are commonly used to reduce lower urinary tract symptoms in prostate cancer patients receiving radiotherapy, their impact on response to radiotherapy remains unknown. Therefore, this pilot study aimed to retrospectively determine if alpha-blockers use, influenced response to radiotherapy for localised prostate cancer. In total, 303 prostate cancer patients were included, consisting of 84 control (alpha-blocker naïve), 72 tamsulosin and 147 prazosin patients. The main outcomes measured were relapse rates (%), time to biochemical relapse (months) and PSA velocity (ng/mL/year). Recurrence free survival was calculated using Kaplan-Meier analysis. Prazosin significantly reduced biochemical relapse at both two and five-years (2.72%, 8.84%) compared to control (22.61%, 34.52%). Recurrence free survival was also significantly higher in the prazosin group. This remained after multivariable analysis (HR: 0.09, 95% CI: 0.04-0.26, p < 0.001). Patients receiving prazosin had a 3.9 times lower relative risk of biochemical relapse compared to control. Although not statistically significant, tamsulosin and prazosin extended recurrence free survival by 13.15 and 9.21 months respectively. We show for the first time that prazosin may reduce risk of prostate cancer recurrence and delay time to biochemical relapse and provides justification for prospective studies to examine its potential as an adjunct treatment option for localised prostate cancer.
Identifiants
pubmed: 32424131
doi: 10.1038/s41598-020-65238-z
pii: 10.1038/s41598-020-65238-z
pmc: PMC7235269
doi:
Substances chimiques
Adrenergic alpha-Antagonists
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8191Références
Australian Institute of Health and Welfare. Prostate Cancer, http://www.aihw.gov.au/cancer/prostate/ (2017).
Sieh, W. et al. Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. The open prostate cancer journal 6, 1–9 (2013).
doi: 10.2174/1876822901306010001
Di Lorenzo, G. Castration-Resistant Prostate Cancer Current and Emerging Treatment Strategies. Drugs (New York, N.Y.) 70, 983–1000 (2010).
Kirby, M., Hirst, C. & Crawford, E. D. Characterising the castration-resistant prostate cancer population: a systematic review. International journal of clinical practice 65, 1180–1192, https://doi.org/10.1111/j.1742-1241.2011.02799.x (2011).
doi: 10.1111/j.1742-1241.2011.02799.x
pubmed: 21995694
Delaney, G. Radiotherapy in cancer care: estimating the optimal utilization from a review of evidence-based clinical guidelines, University of New South Wales, (2007).
Wilcox, S. W. et al. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. Journal of medical imaging and radiation oncology 59, 125–133, https://doi.org/10.1111/1754-9485.12275 (2015).
doi: 10.1111/1754-9485.12275
pubmed: 25588566
Faris, S. & Kaufman, M. LUTS After Radiotherapy for Prostate Cancer: Evaluation and Treatment. Curr Bladder Dysfunc 10, 150–155, https://doi.org/10.1007/s11884-015-0292-9 (2015).
doi: 10.1007/s11884-015-0292-9
Hayama, Y. et al. Lower urinary tract symptoms in patients with prostate cancer under and after intensity-modulated radiation therapy. Low Urin Tract Symptoms 11, O127–O134, https://doi.org/10.1111/luts.12230 (2019).
doi: 10.1111/luts.12230
pubmed: 30010254
Arscott, W. T. et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol 9, 163, https://doi.org/10.1186/1748-717X-9-163 (2014).
doi: 10.1186/1748-717X-9-163
pubmed: 25056726
pmcid: 4118163
Tsumura, H. et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys 81, e385–392, https://doi.org/10.1016/j.ijrobp.2011.04.026 (2011).
doi: 10.1016/j.ijrobp.2011.04.026
pubmed: 21664068
Oyama, N. et al. Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by (125) I brachytherapy for prostate cancer. ISRN Urol 2014, 140654, https://doi.org/10.1155/2014/140654 (2014).
doi: 10.1155/2014/140654
pubmed: 25006516
pmcid: 4004040
Maestri, V. et al. Quinazoline based α1-adrenoreceptor antagonists with potent antiproliferative activity in human prostate cancer cell lines. European Journal of Medicinal Chemistry 136, 259–269, https://doi.org/10.1016/j.ejmech.2017.05.003 (2017).
doi: 10.1016/j.ejmech.2017.05.003
pubmed: 28499171
Batty, M. et al. The Role of alpha1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers. International journal of molecular sciences 17, https://doi.org/10.3390/ijms17081339 (2016).
Lin, S.-C. Prazosin Displays Anticancer Activity against Human Prostate Cancers: Targeting DNA, Cell Cycle. Neoplasia (New York, N.Y.) 9, 830–839 (2007).
doi: 10.1593/neo.07475
Partin, J. V., Anglin, I. E. & Kyprianou, N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. British journal of cancer 88, 1615–1621, https://doi.org/10.1038/sj.bjc.6600961 (2003).
doi: 10.1038/sj.bjc.6600961
pubmed: 12771931
pmcid: 2377124
Keledjian, K. & Kyprianou, N. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. The Journal of urology 169, 1150–1156, https://doi.org/10.1097/01.ju.0000042453.12079.77 (2003).
doi: 10.1097/01.ju.0000042453.12079.77
pubmed: 12576871
Liao, C. H., Guh, J. H., Chueh, S. C. & Yu, H. J. Anti-angiogenic effects and mechanism of prazosin. The Prostate 71, 976–984, https://doi.org/10.1002/pros.21313 (2011).
doi: 10.1002/pros.21313
pubmed: 21541974
Walden, P. D., Globina, Y. & Nieder, A. Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urological Research 32, 261–265, https://doi.org/10.1007/s00240-003-0365-7 (2004).
doi: 10.1007/s00240-003-0365-7
pubmed: 15221243
Benning, C. M. & Kyprianou, N. Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoceptor-independent Action. Cancer Research 62, 597–602 (2002).
pubmed: 11809715
Arencibia, J. M. et al. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. International journal of oncology 27, 1617–1623 (2005).
pubmed: 16273218
Benning, C. M. & Kyprianou, N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 62, 597–602 (2002).
pubmed: 11809715
Forbes, A. Relative cytotoxic potencies and cell death mechanisms of α -adrenoceptor antagonists in prostate cancer cell lines α -Adrenoceptor Antagonists in Prostate Cancer. The Prostate 76, 757–766 (2016).
doi: 10.1002/pros.23167
Pan, S.-L. et al. Identification of Apoptotic and Antiangiogenic Activities of Terazosin in Human Prostate Cancer and Endothelial Cells. The Journal of urology 169, 724–729, https://doi.org/10.1016/S0022-5347(05)64002-5 (2003).
doi: 10.1016/S0022-5347(05)64002-5
pubmed: 12544352
Petty, A. et al. A Small Molecule Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell Migration In Vitro and Prostate Cancer Metastasis In Vivo. Plos One 7, ARTN e42120, https://doi.org/10.1371/journal.pone.0042120 (2012).
Harris, A. M. Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study. The Journal of urology 178, 2176–2180 (2007).
doi: 10.1016/j.juro.2007.06.043
Yamada, D. et al. Reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. International Journal of Urology 20, 1220–1227, https://doi.org/10.1111/iju.12156 (2013).
doi: 10.1111/iju.12156
pubmed: 23600973
Keledjian, K. et al. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. The Prostate 48, 71–78, https://doi.org/10.1002/pros.1083 (2001).
doi: 10.1002/pros.1083
pubmed: 11433417
Heidenreich, A. et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology 65, 124–137, https://doi.org/10.1016/j.eururo.2013.09.046 (2014).
doi: 10.1016/j.eururo.2013.09.046
pubmed: 24207135
van Poppel, H. Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy? Asian Journal of Urology 1, 40–45, https://doi.org/10.1016/j.ajur.2014.09.009 (2014).
doi: 10.1016/j.ajur.2014.09.009
pubmed: 29511636
Sylvester, J. E., Blasko, J. C., Grimm, P. D., Meier, R. & Malmgren, J. A. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. International Journal of Radiation Oncology*Biology*Physics 57, 944–952, https://doi.org/10.1016/S0360-3016(03)00739-9 (2003).
doi: 10.1016/S0360-3016(03)00739-9
Patel, D. A. et al. Preoperative PSA Velocity Is an Independent Prognostic Factor for Relapse After Radical Prostatectomy. Journal of Clinical Oncology 23, 6157–6162, https://doi.org/10.1200/jco.2005.01.2336 (2005).
doi: 10.1200/jco.2005.01.2336
pubmed: 16135482
Han, M., Partin, A. W., Piantadosi, S., Epstein, J. I. & Walsh, P. C. Era specific biochemical recurrence free survival after external beam radiation and brachytherapy for localised prostate cancer: the Seattle experience. The Journal of urology 166, 416–419, https://doi.org/10.1016/S0022-5347(05)65955-1 .
Abramowitz, M. C. et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112, 55–60, https://doi.org/10.1002/cncr.23139 (2008).
doi: 10.1002/cncr.23139
pubmed: 17968996
Berger, A. P. et al. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population. Urology 68, 1067–1071, https://doi.org/10.1016/j.urology.2006.06.020 (2006).
doi: 10.1016/j.urology.2006.06.020
pubmed: 17095070
Ng, M. K. et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU International 103, 872–876, https://doi.org/10.1111/j.1464-410X.2008.08116.x (2009).
doi: 10.1111/j.1464-410X.2008.08116.x
pubmed: 18990146
D’Amico, A. V., Chen, M. H., Roehl, K. A., Catalona, W. J. & Preoperative, P. S. A. velocity and the risk of death from prostate cancer after radical prostatectomy. The New England journal of medicine 351, 125–135, https://doi.org/10.1056/NEJMoa032975 (2004).
doi: 10.1056/NEJMoa032975
pubmed: 15247353
Paller, C. J. & Antonarakis, E. S. Management of Biochemically Recurrent Prostate Cancer After Local Therapy: Evolving Standards of Care and New Directions. Clinical advances in hematology & oncology: H&O 11, 14–23 (2013).
Gotoh, A. A. Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. Pharmacology 90, 242–246 (2012).
doi: 10.1159/000342797
Kyprianou, N. & Benning, C. M. Suppression of Human Prostate Cancer Cell Growth By α1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis. Cancer Research 60, 4550–4555 (2000).
pubmed: 10969806
Yang, G. et al. Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. The Prostate 33, 157–163, 10.1002/(SICI)1097-0045(19971101)33:3<157::AID-PROS2>3.0.CO;2-G (1997).
Zelefsky, M. et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. International Journal of Radiation Oncology • Biology • Physics 41, 491–500, https://doi.org/10.1016/S0360-3016(98)00091-1 .
Soloway, M. S. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5 year results The Journal of urology 167, 112–116, https://doi.org/10.1016/S0022-5347(05)65393-1 .
Murtola, T. J., Kujala, P. M. & Tammela, T. L. J. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. The Prostate 73, 923–931, https://doi.org/10.1002/pros.22638 (2013).
doi: 10.1002/pros.22638
pubmed: 23334943
Heidenreich, A. et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European urology 65, 467–479, https://doi.org/10.1016/j.eururo.2013.11.002 .
Andres. Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men. JAMA: the journal of the American Medical Association 267 (1992).
Bjurlin, M. A. & Loeb, S. PSA Velocity in Risk Stratification of Prostate Cancer. Reviews in urology 15, 204–206 (2013).
pubmed: 24659919
pmcid: 3922327
D’Amico, A. V., Renshaw, A. A., Sussman, B. & Chen, M. Pretreatment psa velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294, 440–447, https://doi.org/10.1001/jama.294.4.440 (2005).
doi: 10.1001/jama.294.4.440
pubmed: 16046650
Anglin, I. E., Glassman, D. T. & Kyprianou, N. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 5, 88–95, https://doi.org/10.1038/sj.pcan.4500561 (2002).
doi: 10.1038/sj.pcan.4500561
pubmed: 12496995
Cal, C., Uslu, R., Gunaydin, G., Ozyurt, C. & Omay, S. B. Doxazosin: a new cytotoxic agent for prostate cancer? BJU Int. 85, 672–675, https://doi.org/10.1046/j.1464-410x.2000.00607.x (2000).
doi: 10.1046/j.1464-410x.2000.00607.x
pubmed: 10759663